Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of A/H1N1 Pandemic Vaccine in Children
NCT00952419Phase 2Completed
- Sponsor
- Sanofi
- Start
- Aug 2009
- Primary completion
- Mar 2010
- Modality
- Live Attenuated Vaccines, Whole Inactivated Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Influenza A (H1N1) vaccine in influenza A H1N1 infection (H1N1) (3 arms), sponsored by Sanofi. Primary endpoints: Number of Participants With Antibody Titers ≥ 10 1/Dilution Against A/California (H1N1 Vaccine) Strain at Day 21, Number of Participants With Antibody Titers ≥ 40 1/Dilution Against A/California (H1N1 Vaccine) Strain at Day 21 and 2 more. Started Aug 2009; status: completed.
02
Drugs
Influenza A (H1N1) vaccine
03
Conditions
influenza A H1N1 infection (H1N1)
Beyond the preview
Go deeper on NCT00952419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00952419.